Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: Results from the BioDay registry
Publication date
2020-09-01
Authors
Spekhorst, Lotte
Ariëns, Lieneke F.M.
Van Der Schaft, J.
Bakker, Daphne S
Kamsteeg, Marijke
Oosting, Albert J
de Ridder, Ilona
Sloeserwij, Annemiek
Romeijn, Geertruida L E
de Graaf, M
Editors
Advisors
Supervisors
Document Type
Comment
Metadata
Show full item recordCollections
License
Abstract
Keywords
Immunology and Allergy, Immunology, Research Support, Non-U.S. Gov't, Letter
Citation
Spekhorst, L S, Ariëns, L F M, van der Schaft, J, Bakker, D S, Kamsteeg, M, Oosting, A J, de Ridder, I, Sloeserwij, A, Romeijn, G L E, de Graaf, M, Haeck, I, Thijs, J L, Schuttelaar, M L A & de Bruin-Weller, M S 2020, 'Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate : Results from the BioDay registry', Allergy, vol. 75, no. 9, pp. 2376-2379. https://doi.org/10.1111/all.14324